Osivax Receives Over EUR 30M in Public Funding to Support Development of Universal Coronavirus & Influenza Vaccines
Osivax Receives Over EUR 30M in Public Funding to Support Development of Universal Coronavirus & Influenza Vaccines
07/08/20, 9:01 AM
Location
lyonIndustry
biotechnology research
Osivax announced today that it has received over EUR 30M in public funding from different sources to support the development of universal vaccines against coronavirus and influenza. The Company’s proprietary oligoDOM® technology enables the development of vaccines that aim to protect the body from all viral influenza strains. By targeting the nucleoprotein, a highly conserved antigen with a low mutation rate found in every flu variation, oligoDOM® has the potential to provide lasting immunity regardless of virus mutation. Osivax is deploying the same approach toward a universal coronavirus vaccine to protect against the current virus, SARS-Cov-2, and future coronavirus strains.
Company Info
Location
lyon, auvergne rhône alpes, france
Additional Info
Osivax is a clinical-stage biopharmaceutical company leveraging its novel, self-assembling nanoparticle platform technology, oligoDOM®, to develop transformative, first-in-class pan-respiratory virus vaccines generating superior T-cell responses in addition to strong and sustained B-cell responses. The company is establishing proof of concept with its broad-spectrum, “universal” influenza candidate, OVX836, which is currently in Phase 2 clinical trials with over 1200 subjects tested and encouraging efficacy proof of concept data. Osivax’ ambition is to develop a pan-respiratory virus vaccine to prevent all strains of influenza and all variants of sarbecovirus in one single shot. The company will expand into other infectious disease indications through combinations and collaborations worldwide.